Sensus Healthcare Inc (NASDAQ:SRTS) insider Joseph C. Sardano sold 6,170 shares of Sensus Healthcare stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $7.50, for a total transaction of $46,275.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Sensus Healthcare stock traded down $0.31 on Friday, hitting $7.16. 35,716 shares of the company’s stock were exchanged, compared to its average volume of 19,582. The stock has a market capitalization of $101.76 million, a PE ratio of -25.57 and a beta of -1.37. Sensus Healthcare Inc has a 1 year low of $4.31 and a 1 year high of $7.71. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.90 and a quick ratio of 3.65.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 2nd. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01). The business had revenue of $6.06 million for the quarter, compared to analysts’ expectations of $6.36 million. Sensus Healthcare had a negative return on equity of 26.19% and a negative net margin of 13.07%. research analysts anticipate that Sensus Healthcare Inc will post -0.17 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Paradigm Capital Management Inc. NY purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth $152,000. BlackRock Inc. purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth $164,000. Commonwealth Equity Services LLC purchased a new position in shares of Sensus Healthcare during the 1st quarter worth $140,000. Finally, Perkins Capital Management Inc. purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth $1,792,000. Institutional investors and hedge funds own 6.21% of the company’s stock.

SRTS has been the topic of several analyst reports. Roth Capital initiated coverage on shares of Sensus Healthcare in a research note on Wednesday, August 1st. They set a “buy” rating and a $12.50 price target on the stock. initiated coverage on shares of Sensus Healthcare in a research note on Friday, July 6th. They set a “buy” rating and a $12.25 price target on the stock. Finally, ValuEngine upgraded shares of Sensus Healthcare from a “hold” rating to a “buy” rating in a research note on Monday, May 7th. Four equities research analysts have rated the stock with a buy rating, Sensus Healthcare has an average rating of “Buy” and an average target price of $11.25.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Story: What are the Different Types of Leveraged Buyouts?

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.